Provided are compounds which are Spt5 inhibitors and which are for use in the treatment diseases and disorders in which inhibiting one or more activities of Spt5 is beneficial, such as, for example, Trinucleotide repeat disorders, obesity, inflammatory diseases, infectious diseases and cancer. The compounds are represented by Formulae I-VII, as defined in the specification.